Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 6th Preview)
-
M&A: Neurocrine’s $2.9B move into Prader-Willi (Soleno buyout)
Neurocrine Biosciences agreed to acquire Soleno Therapeutics in a $2.9 billion deal, picking up Soleno’s Prader-Willi syndrome therapy Vykat (setmelanotide for hyperphagia). Neurocrine will pay $53 per share, a 34% premium to Soleno’s prior close, according to reporting. Vykat was approved in March 2025 to treat hyperphagia in patients with the rare genetic disorder, where constant hunger drives overeating. Analysts have raised questions about the medicine’s growth trajectory and long-term safety profile. The acquisition extends Neurocrine’s rare-disease footprint as it looks to defend and expand revenues ahead of future category and competitor pressures.
-
Regulatory strategy: FDA proposes optional risk-based expedited IND pathway; Takeda drops Denali program
The FDA is floating a new optional, risk-based expedited Investigational New Drug pathway in its FY2027 budget request, intended to speed experimental drugs into early human testing. The proposal would rely on preclinical data that can be confirmed without animal tests. Separately, Takeda ended its partnership with Denali Therapeutics for frontotemporal dementia, returning rights to Denali’s DNL593 drug. Denali said the termination was driven by strategic considerations and not related to efficacy or safety, and it expects to report results from an ongoing early-stage trial later this year. The twin moves underscore how companies are recalibrating early development plans amid changing regulatory expectations and shifting portfolio priorities.
-
Clinical pipeline competition in ophthalmology: Tepezza injectable Phase 3 data
Amgen reported success for an injectable formulation of Tepezza (teprotumumab) in a Phase 3 study for thyroid eye disease, setting up an escalation in competition. The company’s move comes as Viridian Therapeutics has also posted Phase 3 results for a rival program. For Tepezza, the injectable data strengthens Amgen’s position in a category where dosing convenience and durability of response can be decisive for adoption. For the field, incoming Phase 3 readouts are likely to intensify price and access negotiations. The next phase will hinge on comparative safety, practical administration, and differentiation versus competitors as regulators review the datasets.
-
Funding: Syneron Bio raises $150M Series B for peptide platform; Syneron’s prior round cited
Syneron Bio raised $150 million in a Series B round to develop a peptide drug class designed to borrow some of the properties of biologics. The company said the financing will support development of its peptide pipeline and comes after a $100 million round last year. The funding adds to a growing investor push into peptide modalities that aim to combine targeting specificity with improved dosing and manufacturing profiles compared with antibodies. With the round following earlier collaboration activity, Syneron’s next milestones will likely focus on advancing candidates toward clinical proof points and differentiating within a crowded peptide landscape.
-
Corporate AI for trials: BMS partners with Faro Health for AI-driven protocol design
Bristol Myers Squibb is partnering with Faro Health to use AI agents for clinical trial protocol design, drafting, validation and optimization. Faro’s technology structures narrative protocol elements—objectives, endpoints, and schedules—into digital assets that can be used across workflows with traceability. BMS said the collaboration reflects a shift away from document-based development processes, while Faro positioned its approach as a “system of record” for structured protocol design across BMS’s drug development organization. The tie-up matters for execution speed and compliance, particularly as sponsors look to reduce protocol iteration cycles and standardize internal review processes for regulators and research sites.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.